Clinical Trials · NCT06649344
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Enrollment
- 884
- Start date
- Oct 2024
- Locations
- 1 site, China
- Primary endpoint
- Change in HbA1c